Dosing frequency/PD/efficacy relationship of MEN1611 in HER2 amplified, PIK3CA mutated, and refractory to Trastuzumab xenograft model of breast cancer.

被引：0
|
作者：
Fiascarelli, Alessio [1 ]
Merlino, Giuseppe [1 ]
Capano, Stefania [1 ]
Bressan, Alessandro [1 ]
Bigioni, Mario [1 ]
Pellacani, Andrea [2 ]
Binaschi, Monica [1 ]
Salerno, Massimiliano [1 ]
机构：
[1] Menarini Ric, Pomezia, Italy
[2] Menarini Ric, Florence, Italy
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1376
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
    Alessio Fiascarelli
    Giuseppe Merlino
    Stefania Capano
    Simone Talucci
    Diego Bisignano
    Alessandro Bressan
    Daniela Bellarosa
    Corrado Carrisi
    Alessandro Paoli
    Mario Bigioni
    Patrizia Tunici
    Clelia Irrissuto
    Massimiliano Salerno
    Joaquin Arribas
    Elisa de Stanchina
    Maurizio Scaltriti
    Monica Binaschi
    Breast Cancer Research and Treatment, 2023, 199 : 13 - 23
  • [2] Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2+breast cancer
    Fiascarelli, Alessio
    Merlino, Giuseppe
    Capano, Stefania
    Talucci, Simone
    Bisignano, Diego
    Bressan, Alessandro
    Bellarosa, Daniela
    Carrisi, Corrado
    Paoli, Alessandro
    Bigioni, Mario
    Tunici, Patrizia
    Irrissuto, Clelia
    Salerno, Massimiliano
    Arribas, Joaquin
    de Stanchina, Elisa
    Scaltriti, Maurizio
    Binaschi, Monica
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 13 - 23
  • [3] Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2 amplified gastric cancer (GC) cell lines
    Laterza, M. M.
    Belli, V.
    Ciaramella, V.
    Martinelli, E.
    Morgillo, F.
    Ventriglia, J.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Pompella, L.
    Diana, A.
    Orditura, M.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Role of EGFR, HER2 and PIK3CA alterations in male breast cancer
    Rizzolo, P.
    Silvestri, V.
    Falchetti, M.
    Zanna, I.
    Palli, D.
    Ottini, L.
    EJC SUPPLEMENTS, 2010, 8 (05): : 24 - 24
  • [5] PIK3CA mutated, hormonal receptors and HER2: individual targets but partnered in the escape to targeted therapy in breast cancer
    Pinto, Joseph A.
    Gomez, Henry L.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S789 - S793
  • [6] Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab
    Nishimura, Reiki
    Toh, Uhi
    Tanaka, Maki
    Saimura, Michiyo
    Okumura, Yasuhiro
    Saito, Tsuyoshi
    Tanaka, Toshihiro
    Teraoka, Megumi
    Shimada, Kazuo
    Katayama, Kazuhisa
    Koga, Toshihiro
    Kurashita, Kaname
    Hasegawa, Satoshi
    Todoroki, Hidekazu
    Kai, Yuichiro
    Ohi, Yasuyo
    Toyoshima, Satoshi
    Arima, Nobuyuki
    Mitsuyama, Shoshu
    Tamura, Kazuo
    ONCOLOGY, 2017, 93 (01) : 51 - 61
  • [7] Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
    Lopez, Salvatore
    Schwab, Carlton L.
    Cocco, Emiliano
    Bellone, Stefania
    Bonazzoli, Elena
    English, Diana P.
    Schwartz, Peter E.
    Rutherford, Thomas
    Angioli, Roberto
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 312 - 317
  • [8] The unexpected role of p110β in HER2 amplified and PIK3CA mutant breast cancers.
    Costa, Carlotta
    Ebi, Hiromichi
    Faber, Anthony C.
    Nishtala, Madhuri
    Song, Young Chul
    Engelman, Jeffrey A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [9] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Decreased PTEN expression and PIK3CA mutations in HER-2 positive breast cancer.
    Koninki, K.
    Kauraniemi, P.
    Pitkanen, J.
    Isola, J.
    Tanner, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S211 - S211
12345